New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor

J Clin Oncol. 2006 Apr 20;24(12):1957; author reply 1957-8. doi: 10.1200/JCO.2005.05.0450.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Cetuximab
  • Colorectal Neoplasms / drug therapy*
  • Humans
  • Immunohistochemistry
  • Infusions, Intravenous
  • Irinotecan
  • Vascular Endothelial Growth Factor A / blood
  • Vascular Endothelial Growth Factor A / drug effects*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Vascular Endothelial Growth Factor A
  • Irinotecan
  • Cetuximab
  • Camptothecin